Johnson & Johnson (JNJ)
|Net Income (ttm)||15.12B|
|Trading Day||May 12|
|Day's Range||167.95 - 169.80|
|52-Week Range||131.91 - 172.57|
Women who were 30- to 39-years old accounted for the biggest risk group who developed rare blood clots following J&J's Covid vaccine.
Its dividend already pays more than what you'd get from the average stock on the S&P 500.
India's Official Covid-19 Death Count Crosses 250,000 As U.S. Mulls Joint Production Of J&J Vaccine In Country
India reported 4,205 deaths on Wednesday, its worst single-day toll so far as the second wave shows no signs of relenting.
"I do not believe (the J&J vaccine pause) was a setback, I think it really underscored how how seriously we all take safety," Dr. Anthony Fauci told Congress.
Get a look at one of the stocks in the most recent Dividend Growth stocks Model Portfolio.
They're masters of pricing, not to mention their supply chains.
Expert Panel Calls On Norway To Ditch AstraZeneca And Johnson & Johnson Covid Vaccines Over Blood Clot Risks
Neighboring Denmark has already dropped both shots from its vaccination campaign.
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Just 46% of respondents said they were at least somewhat confident in the J&J shot, compared with 69% who said the same for Pfizer and Moderna's vaccines.
Oppenheimer health care analyst on whether vaccine makers should lose sleep over patent waivers
Hartaj Singh, Oppenheimer & Co, on Covid vaccine makers under pressure as the patent waiver conversation continues. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Pete Najarian, Jeff Mil...
Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.
FATE reports a wider Q1 loss on increased R&D expenses.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
While it's easy to get carried away with the speculation, investors should consider these safe stocks to hand down to their progeny. The post 7 Safe Stocks You Can Leave to Your Children appeared first ...
U.S. backs COVID-19 vaccine patent waiver
Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.
Here's why you haven't missed the boat on this blue chip.
If enacted, such a move would hit the smaller vaccine makers particularly hard.
They're built for the long run.
Johnson & Johnson (JNJ) closed at $167.77 in the latest trading session, marking a +1.55% move from the prior day.
The number of Americans who prefer J&J's Covid-19 vaccine declined after the U.S. paused its use to investigate safety, but 17% still say it's their top choice.
Hint: It wasn't the company's COVID-19 vaccine.
The country's health agency said the risks of the vaccine outweigh the benefits, despite the European Medicines Agency saying the opposite.
Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).
These proven stocks look primed to grow your money manifold in the coming years.
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine, 60 million doses of which are in vials and rea...
Investors have been embracing momentum for a while. Is that trend about to reverse?
Whether you're looking for reliable and growing dividends, or you seek high yields, you may find something you like with these dividend ETFs. The post 7 Great ETFs to Buy for Dividend-Hungry Investors a...
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibr...
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate...
From dividends to growth to overall stability, these stocks will give your portfolio a great mix.
Its vaccine might not have panned out as expected, but Merck has more in the works.
There are other factors to consider.
73% of Americans are not willing to get the Johnson & Johnson vaccine: Report
#J&Jvaccine Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance's Sibile Marcellus and Alexis Christoforous to discuss the lat...
Roughly 57% of investor votes cast backed healthcare company Johnson & Johnson's executive pay for 2020, a low level of support for a proposal most shareholders usually rubberstamp.
Johnson & Johnson (NYSE:JNJ) has been in the news for a number of reasons lately.
Experts say the pause should boost public confidence in vaccines.
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the S... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, JNJ's revenue was $82.58 billion, an increase of 0.64% compared to the previous year's $82.06 billion. Earnings were $14.71 billion, a decrease of -2.68%.
According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 186.80, which is an increase of 11.06% from the latest price.